Australian biotechnology company Immutep has entered a clinical trial collaboration agreement with Merck and Pfizer to develop a new cancer immunotherapy combination therapy.
The collaboration will conduct a phase one clinical trial aimed at evaluating the safety and efficacy of the combination of Immutep’s eftilagimod drug with Merck and Pfizer’s avelumab drug in patients with advanced solid malignancies.
Eftilagimod is an antigen presenting cell (APC) activator that stimulates the immune system, while avelumab, branded as Bavencio, is an anti-PD-L1 monoclonal antibody.
Based in Germany, Merck is a biopharmaceutical company, while Pfizer is a US-based developer of medicines, vaccines and other healthcare products.
Enesi Pharma and Walter Reed Army Institute of Research (WRAIR) have partnered to develop a needle-free solid-dose vaccine for Shigella infection.
Shigella is a type of gram-negative, facultative aerobic, rod-shaped bacteria.
Enesi Pharma will develop a solid-dose formulation of WRAIR’s Shigella flexneri 2a artificial Invaplex vaccine, which can be delivered using its ImplaVax technology.
Based in the UK, Enesi Pharma is a developer of novel pharmaceutical products, while WRAIR is a biomedical research laboratory based in the US.
LineaRx, a subsidiary of Applied DNA Sciences, has signed an agreement with Takis to discover and develop DNA-based anti-cancer vaccines.
LineaRx will also partner with Evvivax, a subsidiary of Takis, for the development of vaccines for the animal market.
LineaRx will jointly develop linear DNA expression vectors for two of Takis’ anti-cancer vaccine candidates using its DNA technology, as per the agreement.
The partnership will focus on assessing the antigen-specific immune responses required to achieve therapeutic effects.
Based in Italy, Takis is a biotechnology company engaged in drug discovery and development in the field of oncology, while Evvivax is a developer of innovative therapeutic veterinary cancer vaccines.